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ABSTRACT
Treatment-induced neuroendocrine transdifferentiation (NEtD) complicates 
therapies for metastatic prostate cancer (PCa). Based on evidence that PCa cells 
can transdifferentiate to other neuroectodermally-derived cell lineages in vitro, we 
proposed that NEtD requires first an intermediary reprogramming to metastable 
cancer stem-like cells (CSCs) of a neural class and we demonstrate that several 
different AR+/PSA+ PCa cell lines were efficiently reprogrammed to, maintained 
and propagated as CSCs by growth in androgen-free neural/neural crest (N/NC) 
stem medium. Such reprogrammed cells lost features of prostate differentiation; 
gained features of N/NC stem cells and tumor-initiating potential; were resistant to 
androgen signaling inhibition; and acquired an invasive phenotype in vitro and in vivo. 
When placed back into serum-containing mediums, reprogrammed cells could be re-
differentiated to N-/NC-derived cell lineages or return back to an AR+ prostate-like 
state. Once returned, the AR+ cells were resistant to androgen signaling inhibition. 
Acute androgen deprivation or anti-androgen treatment in serum-containing 
medium led to the transient appearance of a sub-population of cells with similar 
characteristics. Finally, a 132 gene signature derived from reprogrammed PCa cell 
lines distinguished tumors from PCa patients with adverse outcomes. This model may 
explain neural manifestations of PCa associated with lethal disease. The metastable 
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nature of the reprogrammed stem-like PCa cells suggests that cycles of PCa cell 
reprogramming followed by re-differentiation may support disease progression and 
therapeutic resistance. The ability of a gene signature from reprogrammed PCa cells 
to identify tumors from patients with metastasis or PCa-specific mortality implies that 
developmental reprogramming is linked to aggressive tumor behaviors.
INTRODUCTION
Hormone therapies for advanced prostate cancer 
(PCa) can shrink metastatic lesions, slow tumor growth 
and significantly extend patient survival. Yet they 
remain palliative as treated patients usually progress 
to castration resistant disease (CRPC) that portends 
lethality [1]. The clinical success of a new generation 
of anti-androgens in further prolonging survival of 
CRPC patients demonstrates that promiscuous androgen 
receptor (AR) activity plays a role in hormone resistance 
[2]. AR-mediated resistance is complex and can be 
generated by overexpression/amplification of full-length 
AR; by mutations in the AR gene or by expression of 
truncated ARs resulting from altered splicing of AR 
mRNA [3]. For a subset of patients, resistance can also 
be generated by a non-AR-based mechanism referred 
to as neuroendocrine transdifferentation (NEtD) [4, 5]. 
NEtD is associated with a loss of prostate differentiation, 
including AR expression, and a gain of neuroendocrine 
cell features. While neuroendocrine PCa (NEPC) remains 
a relatively limited condition, its occurrence is increasing 
under the constraints of stringent anti-androgen therapies 
and its aggressive nature raises concerns that NEtD will 
increasingly confound opportunities for disease control. 
NEtD is modeled in vitro when androgen-
dependent PCa cells, particularly LNCaP, are placed into 
an androgen-deficient growth medium [6, 7]. NEtD is 
accompanied by an altered cell morphology characterized 
by small central-nucleated cell bodies with elongated 
neurite-like extensions and by overexpressions of 
secretagranins, synaptophysin, neural specific enolase 
and a variety of neuropeptides [6–8]. NEtD is generally 
believed to reflect a direct switch of cell states, putatively 
guided by simple loss(es)/gain(s) of expression or 
function of neuroendocrine (NE) lineage-regulators such 
as REST, AURAK or MYCN [8–10]. In this model, the 
NEtD-inducer regulates the expression of NE lineage 
determinants that awaken and enforce the NEPC 
phenotype. Here we present results of an experimental 
study that contradicts the direct conversion model of NEtD 
and, instead, argues for a model whereby differentiated 
PCa cells must first developmentally reprogram back to a 
neural/neural crest (N/NC) stem cell-like state before re-
differentiating to NE-like cells. 
Our proposal reflects the growing interest in cancer 
stem cells (CSCs) as mediators of aggressive prostate 
tumor behaviors. Putative CSCs have been distinguished 
and selectively enriched from tumor cell populations 
based on high expression of certain cell surface antigens 
(CD49b/29 [integrin-α
2
β
1
], CD133, and CD44) [11, 12]; 
high expression of detoxifying enzymes [13] or membrane 
transporters [14] and based upon low expression of the 
prostate-specific differentiation marker, prostate specific 
antigen (PSA) [15]. Such cells tend to overexpress 
Yamanaka Factors Oct3/4 [Pou5f1], Nanog and Sox2 
[16]. Enriched populations of CSCs typically have high 
clonogenicity in culture and the ability to grow in an 
anchorage-independent manner leading to the formation 
of multicellular spheroids. While they tend to have slower 
proliferation rates compared to non-CSCs, they can form 
tumors from very low numbers of cells xenografted into 
immune-deficient mice.  
CSCs may represent a remnant of the original 
transforming event within a prostate epithelial stem cell 
population [17, 18]. Their propagation over time through 
asymmetric replication, to generate a slower replicating 
CSC and a more rapid proliferating differentiated cancer 
cell, would account for the dominance of differentiated 
cells in tumors [18, 19]. However, there is increasing 
evidence that CSCs can also be generated through de-
differentiation from non-CSCs under the influence of 
idiopathic activation of polycomb or through activation of 
an Epithelial to Mesenchymal Transition (EMT) program 
[19–21]. While evidence supports prostate CSC resistance 
to androgen deprivation (AD) therapy [11, 15] and anti-
mitotics [22], prostate CSCs remain poorly characterized 
for their ability to metastasize and for other qualities 
associated with pluripotent/multipotent stem cells such as 
the ability to differentiate to alternate cell lineages.     
Evidence, presented here, of LNCaP cell 
transdifferentiation to other neural/neural crest (N/NC) 
stem cell-derived lineages in vitro, under chronic AD, 
caused us to re-evaluate the paradigm of direct NEtD. 
We detected a complex spectrum of gene expression 
changes in chronic AD LNCaPs that was consistent 
with the presence of multiple transdifferentiated N/NC-
derived cell lineages rather than exclusively NE-like cells. 
Indeed, others have already reported that LNCaP cells can 
acquire a morphological phenotype and transcriptome 
resembling that of adult neurons [23]. Such a spectrum 
of transdifferentiation might require an intermediate N/
NC stem-like state and we sought to reveal, expand and 
characterize this intermediary state using an androgen-
free N/NC stem cell medium to “reprogram” differentiated 
PCa cells. By finding the means to efficiently reprogram, 
without genetic manipulation, maintain and further 
propagate PCa cells in this novel transitional stem-like 
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state, we have been able to characterize features that show 
they differ from other types of PCa CSCs and imply that 
they represent a more aggressive form of PCa.
RESULTS
Conditional reprogramming of PCa cells to N/
NC stem-like cells with resistance to androgen 
therapeutics and enhanced invasive/metastatic 
properties
LNCaP cells undergo NEtD under acute AD [6, 7]. 
We performed comparative gene microarray expression 
analyses using RNAs from parental or 15-day AD LNCaP 
cells to identify genes more chronically upregulated after 
AD. Outcomes showed striking upregulation of genes 
specific for sensory and peripheral neurons, sensory tissue 
development and function, facial/tooth development and 
cardiovascular development amongst others, collectively 
representing a heterogeneous assortment of potential 
neuroectodermal cell lineages that arise from N/NC stem 
cells [24]. Functional annotation of upregulated genes 
showed that most clustered into three categories that 
included genes involved in N/NC development, functions 
of N/NC stem cells and markers of N/NC-derived 
cell lineages (Figure 1A, Supplementary Table 1). We 
reasoned that these observations suggested the possibility 
that transdifferentiation might be mediated by transient 
reprogramming of PCa cells to an intermediate N/NC stem 
cell-like state that then re-differentiates into NE and other 
neuroectodermal-derived cell lineages.   
We further reasoned that an androgen-free medium 
that supports growth of N/NC stem cells might enable 
conditional reprogramming to this intermediate state 
and allow us to stably propagate such cells for further 
analyses. When we cultured any of four AR+ PCa cell 
lines (LNCaP, VCaP, LAPC4 and 22Rv1) in N/NC Stem-
Transition Medium (STM), they underwent a marked 
change in morphology, characterized by transition to 
cells with a rounded body, enlarged nuclei and strikingly 
distinct nucleoli (Figure 1B) over the period of a week. 
Unlike parental PCa cells that tend to separate until 
confluence, cells placed into STM clustered together over 
time, forming 3-dimensional mats. Upon transfer into 
fresh STM, cells thereafter formed small, poorly-attached 
rosettes that grew into spheroids (Figure 1B, 1C). This 
non-adherent growth pattern was maintained through 
further passaging and we have transferred cells as many 
as 20 times in STM without deviation from this pattern. 
While cells continue to grow in the absence of androgen, 
their doubling time is approximately 3 times longer 
than parentals (Figure 1D). We used colony-forming 
and sphere-forming assays to quantify the efficiency of 
this transition for LNCaP cells, indicating a conversion 
efficiency of approximately 60% and 80% respectively 
(Figure 1E, 1F). Reprogramming did not occur with 
standard embryonic stem cell (ESC) medium or when the 
neural stem supplement was removed (data not shown). 
When tested in non-adherent plate colony-forming assays, 
STM also strongly promoted the formation of proliferative 
spheroidal colonies compared to standard PCa cell culture 
media, with or without androgen (Figure 1G). 
The changes in morphology and growth patterns 
coincided with a notable change in gene expression. 
AR and PSA mRNA and protein expressions were 
suppressed, including truncated AR-V7 in 22Rv1 cells 
[3] (Figure 2A–2C). For LAPC4, LNCaP and VCaP cells, 
this was consistent with a significant loss of sensitivity to 
growth inhibition by enzalutamide (Figure 2D). Further, 
evaluation of a small panel of stem cell-associated genes 
showed that key Yamanaka Factors were commonly 
overexpressed in all treated PCa cells (Figure 3A). 
All four reprogrammed cell lines also shared a striking 
increase in expression of BMI1 and phosphorlyated-AKT 
protein whereas EZH2 protein expression was reduced 
or relatively unchanged (Figure 3B). For LNCaP cells, 
spheroid formation in STM under non-adherent conditions 
was strongly inhibited by the presence of a BMI1 inhibitor 
(PTC-209), a PI3-kinase inhibitor (LY294002) or an AKT 
inhibitor (MK2206) (Figure 3C).
Heat maps of differentially expressed genes 
(compared to their respective parentals) showed that 
reprogrammed LNCaP, VCaP and LAPC4 cells had 
distinct clusters of over- or under-expressed genes that 
may reflect differing genomic alterations within each cell 
line (Supplementary Figure 1). The common differentially 
expressed gene sets, however, were significantly enriched 
for genes functionally characterized by involvement 
in cell development, morphology, movement and cell 
death and survival (Figure 3D). On an individual basis, 
gene set enrichment analysis (GSEA) Hallmarks for 
Androgen Response Genes were significantly reduced 
while Prostate Cancer-Down Genes were significantly 
enriched in reprogrammed cells (Figure 3E). There was 
also significant enrichment for Stem Cell Genes in the 
Boquest [25] and Lim [26] stem cell datasets (Figure 3E). 
Unique to this model, reprogrammed cells 
overexpressed genes and proteins associated with N/
NC stem cells (Figure 4A–4C). Upregulated genes in 
reprogrammed LNCaPs were significantly enriched 
in both the Kreitzer [27] and Lee [28] NC stem cell 
gene expression databases (Figure 4D). Accordingly, 
reprogrammed LNCaP cells displayed an altered cell 
surface marker profile that was congruent with a NC-
specific stem cell identity [29] including CD29High/
CD15Low, with increased NRCAM, CD271(NGFR) and 
CD57(HNK1) expression (Figure 4E, 4F) whereas they 
lacked expression of surface markers CD133 and CD44 
(Figure 4G) that are inconsistent markers of prostate 
CSCs [30–32]. Similarly, reprogrammed VCaP cells 
also overexpress N/NC markers CD271/NGFR, NRCaM 
and CD57/HNK1, as well as CD44 (Supplementary 
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Figure 1: Developmental reprogramming of PCa Cells to a stem-like intermediate. (A) Chronic AD of LNCaP cells 
upregulated genes associated with N/NC stem cells and derivative tissues. LNCaP cells (Left) cultured in androgen-depleted medium 
for 15-days undergo a morphological transformation (Middle), and overexpress genes associated with N/NC stem cells and derivative 
tissues shown on heat-mapping (Right). (B) Representative phase-contrast images of LNCaP cells over two weeks of culture in STM. 
(C) Representative phase-contrast images of VCaP, LAPC4 or 22Rv1 spheroids after 14-day STM-mediated reprogramming. Scale bars 
represent 100 µm. (D) Proliferation assays of parental LNCaP (P) and reprogrammed stem-like LNCaP cells (SL) showed that the doubling 
time of LNCaP-SL is significantly greater than parentals. Mean ± standard error; **P < 0.01. (E) Clone formation of dispersed LNCaP cells 
grown in FBS or STM medium indicates that reprogramming occurs in at least 57% of LNCaP cells plated. Mean ± standard deviation; 
***P < 0.001. (F) The percentage of spheroids (diameters greater than 100 µm) is significantly greater in STM cultured LNCaP cells 
compared to FBS cultured LNCaP cells, over 14 days. Mean ± standard deviation shown; ****P < 0.0001. (G) Spheroid colony formation 
assay of LNCaP cells cultured in FBS, CSS or STM on attachment-free plates shows advantage of STM compared to standard culture 
medium (RPMI) with (FBS) or without androgen (CSS). Mean ± standard deviation; ***P < 0.001; ****P < 0.0001.  
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Figure 2). STM-reprogrammed LNCaPs also readily 
differentiated to NC-derived cell lineages such as 
neuron-, oligodendrocyte-, osteoblast- or glia-like cells 
in androgen-free lineage-specific differentiation media, 
as shown by their representative morphologies as well 
as by the expression of lineage-specific mRNAs and 
proteins (Figure 5A–5C, Supplementary Figure 3). 
Collectively, these characteristics support the idea that 
STM-driven reprogramming enabled LNCaP conversion 
to a multipotent N/NC stem-like state. 
Reprogrammed LNCaPs were significantly more 
capable of initiating tumors from small numbers of 
Figure 2: Androgen Receptor axis down-regulation in developmentally reprogrammed PCa cells. (A) AR and PSA mRNA 
expression, measured by RT-qPCR, is down-regulated in reprogrammed (SL) PCa cells compared to parentals. Bars represent relative 
expressions compared to parental cell lines. Mean ± standard error; **P < 0.01; ***P < 0.001. (B) Secretion of PSA into cell medium was 
significantly downregulated in LNCaP-SL cells over 48 hours compared to parental cells. Mean ± standard deviation; ***P < 0.001. (C) 
Western Blot analyses of parental and reprogrammed PCa cells showed down-regulation of AR and AR-variant protein. (D) Relative growth 
inhibition (7-days) of LAPC4, LNCaP and VCaP parental and stem-like cells with increasing dosages of enzalutamide. Mean ± standard 
deviation; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 
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cells xenografted into intact or pre-castrated male mice 
(Table 1). Tumors formed from reprogrammed (ARLow) 
cells were composed of AR+ cells, even in castrates 
(Supplementary Figure 4). NC stem cells are recognized 
for their predisposition to EMT and invasion [24, 33]. Thus 
the overexpression of EMT genes (Figure 6A, 6B) and loss 
of E-cadherin expression (Figure 6C) in reprogrammed 
PCa cell lines remains consistent with an invasive 
NC stem-like phenotype. Accordingly, we observed 
significantly increased in vitro invasion through a Matrigel-
coated membrane for developmentally reprogrammed 
LNCaP cells (Figure 6D). Furthermore, all reprogrammed 
cell lines displayed increased invasive behaviors in vivo 
in a zebrafish xenograft model compared to parental cells 
(Figure 6E). 
The metastable nature of STM-reprogrammed 
cells also allowed re-differentiation to NE-like cells 
when switched to androgen-free medium (Figure 7A) 
or return to prostate-like cells with re-expression of 
AR in medium containing androgen (Figure 7B, 7C, 
Supplementary Figure 5). We sequentially reprogrammed 
then re-differentiated LNCaP cells back to prostate-like 
cells at least 6 times, showing the remarkable plasticity 
of the phenotypes. By 6 sequential re-cyclings though, 
Figure 3: Stem cell-like features of developmentally reprogrammed PCa cells. (A) Expression of mRNAs for OCT3/4, 
SOX2 and NANOG is increased in reprogrammed PCa cells. Mean ± standard error; *P < 0.05; **P < 0.01; ***P < 0.001. (B) Western 
Blot analyses showed overexpression of BMI1 and phosphorylated-AKT protein in reprogrammed PCa cells. (C) Sphere-forming assays 
indicate significantly smaller spheroid formation of LNCaP cells during developmental reprogramming when AKT and BMI1 pathways 
are targeted with inhibitors LY294002, MK2206, or PTC209. Mean ± standard deviation; ****P < 0.0001. (D) Ingenuity analyses of genes 
differentially expressed (p < 0.05, fold-change > 2.0) in reprogrammed LNCaP, VCaP, and LAPC4 cells indicate that STM-reprogramming 
induces a significant enrichment of cellular functions related to cancer stem cell phenotypes. (E) Gene Set Enrichment Analyses (GSEA) 
of genes differentially expressed (p < 0.05, fold-change > 1.5) in reprogrammed LNCaP, VCaP, and LAPC4 indicate reprogramming is 
inversely correlated with Androgen Response Genes and significantly enriched in Prostate Cancer-Down Genes (Liu dataset [56]), and 
Stem Cell Genes (Boquest and Lim datasets [25, 26]). 
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AR+ “returned” R6 cells showed significant androgen 
growth-independence, being resistant to both androgen 
deprivation and enzalutamide (Figure 7D, 7E), despite 
overexpressing full-length AR protein (data not shown). 
Finally, acute exposure of parental LNCaP cells to 
androgen-free medium or enzalutamide increased the 
population of CD29High cells, (Figure 7F, Supplementary 
Figure 6A). This population was transient and was lost 
upon chronic selection under AD to generate androgen 
growth-insensitive LNCaP-AI cells. LNCaP-AI cells, 
however, remain sensitive to enzalutamide and acute 
treatment with enzalutamide also increased the CD29Hi/
CD133Lo/CD44Lo population (Figure 7F, Supplementary 
Figure 6B, 6C). 
Gene expression changes induced by STM-
reprogramming are biologically relevant  
Gene Set Enrichment Analysis (GSEA) showed that 
genes overexpressed in reprogrammed LNCaPs (p < 0.05, 
fc > 1.5) were positively enriched in the transcriptomes of 
LNCaP xenografts following castration of the host mouse 
(Figure 8A, 8B). Normalized enrichment scores (NES) reach 
highest significance in regressing and PSA-nadir tumors. 
Afterwards, NES diminished again to non-significance 
as tumors relapsed to castration-resistance. Moreover, we 
observed a reverse correlation of NES with serum PSAs in 
the xenografts (Figure 8C), suggesting that residual tumor 
cells at PSA nadir that will repopulate the recurrent tumor 
are enriched for an mRNA expression profile associated 
with the in vitro reprogramming of tumor cells.
Finally, global gene expression profiling of three 
reprogrammed cell lines (LNCaP, VCaP and LAPC4) 
showed an overlapping set of 132 genes commonly 
altered by reprogramming, and contained several N/NC 
stem cell genes including ALCAM(CD166) and SOX9 
(Figure 9A, 9B, Supplementary Table 2). Use of this 
set as a gene signature to analyze clinically-annotated 
human prostate tumor gene expression datasets showed 
significant enrichment in patients with biochemical 
recurrence (BCR) or the presence of overt metastasis 
(METS) in the Mayo Clinic (MC) I and II, Cleveland 
Clinic Foundation (CCF) and Memorial Sloan Kettering 
Cancer Center (MSKCC) datasets (Figure 9C–9F, 
Supplementary Tables 3,4).  The gene signature was also 
significantly enriched in tumors from patients with PCa-
specific mortality (PCSM) in MCI/II datasets whereas 
the CCF and MSKCC datasets were not powered for this 
determination. Relevant Kaplan-Mayer survival curves 
in the MCII dataset showed that the presence of the gene 
signature in primary tumors was a significant prognostic 
marker for BCR, METS and PCSM. This prognostic 
value was an independent predictor of METS and PCSM 
in MCII as was shown by its significance in univariant 
as well as multivariant analyses (in Supplementary 
Table 4). 
DISCUSSION
Based on re-evaluation of in vitro NEtD in LNCaP 
cells, we proposed the existence of a transient N/NC stem-
like state, induced as a consequence of therapy, which 
Table 1: Subcutaneous tumor xenografts formed from parental or STM-reprogrammed LNCaP 
cells in intact and castrated nude mice
Number of Cells 
Xenografted
Tumors/Xenograft
Parental LNCaP Reprogrammed LNCaP
Intact
 Nude Mice
2 × 106 4/8 N/A
1 × 106 5/8 N/A
5 × 105 0/8 N/A
1 × 105 0/8 N/A
1.25 × 104 N/A 4/8
6.25 × 103 N/A 3/8
1.25 × 103 N/A 2/8
1.252 × 102 N/A 1/8
Castrated Nude Mice
1 × 106 3/8 N/A
1 × 105 0/8 N/A
5 × 104 0/8 2/8
1 × 104 0/8 6/8
1 × 103 N/A 1/8
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Figure 4: Developmentally reprogrammed PCa cells have characteristics of NC stem cells. (A) Immunofluorescence staining 
for NESTIN, a neuroectodermal stem cell marker, in parental and developmentally reprogrammed LNCaP cells. (B) Immunofluorescence 
staining of BRN3A, a neuronal transcription factor, in parental and developmentally reprogrammed LNCaP cells. Scale bars represent 
20 µm. (C) qPCR analyses indicate that reprogrammed stem-like PCa cells overexpress genes associated with NC stem cells compared to 
parental cells. Mean ± standard error; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (D) GSEA shows significant enrichment of NC 
stem cell genes in the Kreitzer and Lee neural crest stem cell datasets [27, 28] in reprogrammed LNCaP cells. (E) FACS analyses indicate 
that reprogramming increases the population of CD29High/CD15- cells. (F) FACS profiling of CD29Moderate and CD29High LNCaP-SL cells 
showed that reprogrammed CD29High cells overexpress CD271, NRCaM, CD166 and CD57, surface markers of neural crest stem cells. (G) 
FACS analyses demonstrate that expression of CD133 and CD44 remain unchanged after developmental reprogramming in LNCaP cells.
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Figure 5: Reprogrammed PCa cells can differentiate to N/NC-derived cell lineages. (A–C) Morphological features and 
expression of cell lineage biomarkers in LNCaP-SL cells cultured in neuronal (A), oligodendrocyte (B) or osteoblast (C) differentiation 
mediums (Diff Media) for 14 days, indicating the acquisition of relevant morphology (Left), mRNA expressions (Middle) or protein 
expressions by IF (Right) indicative of neurons, oligodendrocytes or osteoblasts by LNCaP-SL cells. Mean ± standard error; *P < 0.05; 
**P < 0.01; ***P < 0.001. 
Figure 6: Reprogrammed PCa cells possess increased invasive/metastatic abilities. (A) GSEA indicates a significant 
enrichment of EMT genes in LNCaP-SL cells. (B) qPCR analyses show that reprogrammed LNCaP-SL cells overexpress mRNA of 
key EMT markers. Mean ± standard error; *P < 0.05; **P < 0.01; ***P < 0.001. (C) Western Blot demonstrates loss of E-Cadherin 
in reprogrammed PCa cells indicating increased EMT phenotype. (D) Reprogrammed LNCaP-SL cells demonstrate increased invasion 
through a Matrigel-coated membrane in in vitro invasion assays compared to parental LNCaP cells. Mean ± standard error; *P < 0.05. (E) 
Reprogrammed stem-like PCa cells are more invasive/metastatic in zebrafish assays (Left). Representative photomicrographs of VCaP and 
VCaP-SL xenografted fish illustrates dispersal of fluorescently-labelled VCaP-SL cells within the caudal region (Right). 
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mediates NEtD-driven resistance of PCa. We sought to 
capture and characterize PCa cells in this state with the 
use of an androgen-free N/NC stem cell medium. Four 
different AR+/PSA+ PCa cell lines cultured in STM 
underwent a similar morphological transition and readily 
formed spheroids similar to the growth patterns of rare 
prostate CSCs. These features are strikingly different from 
in vitro NE-transdifferentiated PCa cells in androgen-
depleted medium. Additionally, cells continued to grow 
in STM whereas NEtD in vitro results in a growth-
quiescence. The use of N/NC stem cell medium was 
crucial for PCa cell reprogramming; it did not occur when 
cells were grown in previously reported ESC mediums or 
with medium supplemented with EGF and bFGF alone, 
indicating that it is distinct from previously described CSC 
expansion paradigms where these two supplements often 
suffice [34]. STM differs from standard mediums used to 
culture AR+ PCa cells in that it lacks serum and androgen 
and is supplemented with recombinant EGF, bFGF and 
a commercial neural supplement used in the culture of 
neural/neural crest stem cells. Due to the proprietary 
nature of this neural stem cell supplement, we are not 
privilege to its contents. However we have detected the 
presence of a neural-derived regulatory protein, Sema3C 
(data not shown), that may indicate the inclusion of a 
neural tissue extract. Given reports that PCa cells express 
a Semaphorin receptor (Plexin B1) and are influenced 
by Semaphorins [35, 36], perhaps Semaphorin signaling 
plays some role in the model we described. 
Microscopically, we observed virtually the entire 
population of plated cells undergoing this morphological 
transformation and clustering.  We quantitatively 
determined reprogramming efficiency for LNCaP cells 
at approximately 60–80% of the STM-treated parental 
population, depending on the assay employed. This may 
be an underestimate since poorly-adherent STM clones 
were likely lost during medium changes in the assays. 
Observations on the three other AR+ PCa cells switched 
Figure 7: Reprogramming in vitro by androgen-deprivation and acquired therapy resistance. (A) LNCaP-SL cells re-
differentiate to neuroendocrine-like cells within 5-days in RPMI with CSS. (B) LNCaP-SL cells regain the typical morphology of LNCaP 
cells within 5-days in RPMI with FBS. Scale bars represents 100 µm. (C) Western Blot shows that re-differentiated LNCaP cells regain 
AR and E-Cadherin expression while retaining higher phosphorylated-AKT and BMI1 protein expression. (D) Loss of growth inhibition 
when LNCaP-R6 cells were grown in RPMI with CSS medium compared to parental LNCaP demonstrates acquired resistance to androgen-
deprivation. (E) Loss of growth inhibition of LNCaP-R6 cells grown in RPMI with FBS supplemented with 1 µM enzalutamide compared 
to parental cells demonstrates acquired resistance to enzalutamide. Mean ± standard error; *P < 0.05; **P < 0.01; ***P < 0.001. (F) FACS 
analyses shows the increase of CD29SuperHigh populations in reprogrammed LNCaP cells and in parental LNCaP cultured in RPMI with CSS 
(P+CSS) or RPMI with FBS and 10 µM enzalutamide (P+Enz) for 3 days, LNCaP androgen-independent cells (AI) cultured in CSS (AI) or 
in the presence of 10 µM enzalutamide (AI+Enz). Mean ± standard error; *P < 0.05; **P < 0.01; ***P < 0.001. 
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to STM showed a similar high rate of morphological 
conversion.  
Like prostate CSCs enriched by surface antigen 
expression or other methods, STM-reprogrammed cells 
showed markedly reduced expression of AR and PSA. 
The loss of AR was commensurate with development 
of resistance to the growth-inhibitory effects of the AR 
antagonist, enzalutamide. For 22Rv1 and VCaP cells, 
which overexpress AR-V7, a truncated AR variant, 
STM-reprogramming suppressed expression of both full-
length and AR-V7. Thus, despite the belief that truncated 
ARs constitutively drive AR signaling, the loss of AR-
V7 expression in reprogrammed cells suggest that it is 
not replacing differentiation functions activated by full-
length AR and this is supported by studies contrasting 
the transcriptome of AR-V7 and full-length AR [37]. 
STM induced marked upregulation of Yamanaka 
factors, phosphorylated-AKT and BMI1, thought to 
represent genes/proteins active in CSCs [38, 39]. BMI1 
overexpression is already associated with progression 
of PCa and acquired resistance to therapeutics [39, 40]. 
It is part of the polycomb reader complex that plays a 
role in epigenetic gene silencing and is required for 
self-renewal of neural and other stem cell types [41]. In 
contrast to BMI1, EZH2 expression was significantly 
reduced in most cells by STM-reprogramming.  We 
are currently exploring whether the reduction in EZH2 
expression may be a factor in the metastable nature of 
STM-reprogrammed PCa cells.  
Collectively, these changes support the idea 
that STM triggered a developmental reprogramming 
process that returned PCa cells to a more stem like state, 
graphically described in Figure 10. Increased expression 
of N/NC-specific stem markers (NESTIN, BRN3A, SOX9, 
SOX10, TFAP2A and ASCL1) and cell surface proteins 
(NRCAM, NGFR, ALCAM, HNK-1 and Integrin-β
1
) on 
reprogrammed cells addresses the N-/NC-specific stem-
like identity of the reprogrammed state as was proposed. 
Our ability to subsequently direct re-differentiation 
of reprogrammed LNCaP cells to N/NC-derived cell 
Figure 8: Reprogramming in vivo by androgen-deprivation and acquired therapy resistance. (A–B) Genes overexpressed in 
reprogrammed LNCaP cells are positively enriched in the transcriptomes of LNCaP xenografts after castration of hosts. GSEA-determined 
normalized enrichment scores shows significant enrichment of stem-like overexpressed genes in RNAs from regressing LNCaP xenografts 
after castration of the host (n = 6) and at PSA nadir (n = 9) whereas these genes were not enriched in xenografts prior to castration (n = 11) 
or in recurrent castrate-resistant tumors (n = 12). Mean ± standard error. (C) The Normalized Enrichment Score (NES) of LNCaP-SL cells 
compared to LNCaP xenografts before and after castration is inversely and significantly correlated with PSA levels in the blood of murine 
xenograft hosts.
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Figure 9: Reprogrammed PCa cells share a gene signature that correlates with adverse outcomes in patients. 
(A) Venn Diagram of genes differentially expressed (p < 0.05, fold-change > 2) in three reprogrammed PCa cell lines share a common 132 
gene signature. (B) Heatmap of the top 90 differentially expressed genes (p < 0.05, fold-change > 2) in reprogrammed LNCaP, VCaP and 
LAPC4 PCa cell lines. The complete gene list is found in Supplementary Table 2. (C–F) Enrichment of the 132 gene reprogrammed PCa 
cell signature was assessed in the MCII dataset (see supplementary data for results in other patient cohorts) and correlated with PCa patient 
clinical outcomes, including biochemical recurrence (BCR), development of metastasis (METS) and Prostate Cancer Specific Mortality 
(PCSM). (C) Patient annotation matrix and waterfall plots showing the 132 gene signature score in waterfall plots above a patient annotation 
matrix. Each column of the waterfall plot relates to a column in the annotation matrix and represents one patient. The rows of the annotation 
matrix indicate the events which the patients experienced. (D) The 132 gene signature score is significantly higher (p = 2.55 × 10–5, 
AUC = 0.66) in patients with BCR and a high gene signature score (green line) in primary tumors predicts BCR (p = 0.046). (E) The 132 
gene signature score is significantly higher (p = 3.97 × 10–8, AUC=0.72) in patients with METS and a high gene signature score (green line) 
in primary tumors predicts the development of metastases (p = 1.74 × 10–6). (F) The 132 gene signature score is significantly correlated 
(p = 4.98 × 10–4, AUC = 0.69) to prostate cancer specific mortality and a high gene signature score (green line) in primary tumors is 
significantly correlated with poor prognosis (p = 7.93 × 10–4).
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lineages (neuron, oligodendrocyte, osteoblast and glia) 
using lineage-specific differentiation mediums further 
demonstrates their multipotent N/NC stem-like state. 
Despite the many stem-like characteristics, reprogrammed 
PCa cells differ from more commonly described CSCs 
in that they all lacked surface expression of CD133. 
Whereas reprogrammed LNCaP and LAPC4 cells did 
not overexpress surface CD44, reprogrammed VCaP and 
22Rv1 cells did overexpress it.  While the current focus 
is on CSCs that are marked by CD133 and CD44, our 
results reinforce incongruous reports of stem cell-like 
characteristics in cancer cells that lack expression of these 
antigens [30–32].
Reprogramming also generated a more aggressive 
PCa cell. Reprogrammed LNCaPs showed high tumor-
initiating capacity in both intact and castrated male mice 
that was in striking contrast to parentals that required 
at least one million cells to form tumors. Likewise, 
NC stem cells are known for their invasive abilities 
during embryonic development and features of EMT 
[33]. In reprogrammed cells, these EMT features were 
correlated with an overall enrichment for expression 
of EMT-related genes, increased expression of SNAI2, 
ZEB1 and VIM, reduced expression of E-cadherin and 
increased invasiveness in vitro and in vivo. Accordingly, 
all four reprogrammed PCa cell lines were significantly 
more invasive in zebrafish assays than their parental 
counterparts. This type of developmental plasticity 
that increases invasiveness and generates neural- and 
even bone-like phenotypes might facilitate metastatic 
dissemination of PCa. Perineural invasion at the primary 
site is a harbinger of metastatic disease and the neural-type 
plasticity that we observed could facilitate the interaction 
of PCa cells with nerves [42, 43]. Furthermore, with 
evidence that PCa cells use neural networks to metastasize 
to bone, the neural and bone mimicry generated in our 
in vitro system suggests that this plasticity may foster 
dissemination through nerves and establishment in bone 
[44–46]. Indeed, our observations that acute treatment 
with AR inhibitors enabled a transient increase in the 
Figure 10: Schematic pathway for the neural/neural crest stem cell-mediated transdifferentiation of prostate cancer 
cells. Based on the outcomes of this study, we propose a model whereby androgen receptor pathway inhibition triggers a developmental 
reprogramming process that results in a metastable cancer stem-like state that resembles neural/neural crest stem cells. These N/NC 
stem-like cells may acquire features of differentiated N/NC derived cell lineages when placed into cell-specific differentiation mediums. 
Depending on the cellular microenvironment, these developmentally reprogrammed cells may transdifferentiate to neuroendocrine-like or 
other therapy resistant PCa cell types.
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population of high Integrin-β
1
 marked cells might 
explain findings showing that hormonal agents increased 
metastatic dissemination of PCa [47]. 
The reprogrammed phenotype was metastable 
while cells were passaged and maintained in STM. Re-
exposure to standard culture medium restored PCa cells 
to their adherent epithelial state with re-expression of AR. 
Likewise, ARLow reprogrammed LNCaP cells xenografted 
into mice formed tumors composed of cells with extensive 
nuclear AR staining, even in pre-castrates. Despite our 
interest in the role of NEtD and progression to castration 
resistance, the vast majority of castration/enzalutamide 
resistant PCa cells express AR and show indications of 
continued dependence on AR activity [2]. The castration 
resistant nature of tumors formed after xenografting 
of ARLow reprogrammed LNCaP cells led us to study 
whether in vitro cycles of reprogramming followed by re-
differentiation could generate an AR+ LNCaP variant able 
to grow in androgen-depleted medium. Indeed, six cycles 
of repeated reprogramming-redifferentiation yielded AR+ 
androgen growth-independent cells that were also resistant 
to enzalutamide. As we found that phosphorylated-AKT 
levels remained elevated in returned AR+ PCa cell lines, 
this resistance may be driven by an AKT-dependent 
mechanism as also occurs in vivo [48].  
In vivo relevance of the STM reprogramming 
paradigm is supported by the positive enrichment of 
genes overexpressed in reprogrammed LNCaP cells in the 
transcriptomes of LNCaP xenografts only during the acute 
period after castration. This transient correlation addresses 
our hypothesis that the reprogrammed phenotype 
represents an intermediate state leading to resistance 
(Figure 10). Clinical relevance of the reprogramming 
paradigm is demonstrated by the ability of the common 
gene signature of in vitro reprogrammed PCa cells 
to identify patients with adverse outcomes. There is 
extensive interest in stratifying clinical outcomes of PCa 
based upon a transcriptomic “classifier” gene signature 
applied to primary tumors. To date, these predictive 
signatures were derived from comparisons of individual 
tumor transcriptomes collected from large patient groups 
with differing clinical end-points [49, 50]. Our signature, 
in contrast, was derived from differential gene expression 
analyses of novel PCa cell models. This correlation 
suggests that primary tumors from patients with aggressive 
disease may harbor a stable subset of CSCs that resemble 
reprogrammed N/NC stem-like cells. Alternatively, such 
tumors may have a larger population of cells that are 
cycling between this transitional CSC-like state and a 
differentiated state, perhaps due to adverse aspects of the 
tumor microenvironment (hypoxia, low androgen levels). 
With regard to therapeutic considerations, based 
upon the upregulated expressions of phosphorylated-
AKT and BMI1 protein in reprogrammed cells, we 
found that small molecule inhibitors of these proteins 
effectively blocked clonogenicity and growth in STM. 
Both of these proteins are already considered to be 
targets for better control of metastatic CRPC [38–40]. 
This raises the possibility that their function in CRPC is 
linked to developmental reprogramming. Collectively, 
our results suggest that therapy-induced developmental 
reprogramming provides another mechanism for generating 
aggressive, therapy-resistant PCa cells. Our findings also 
support the idea that there may be more than one class of 
CSC within a prostate tumor and that each may contribute 
differently to clinical outcomes in PCa patients.
MATERIALS AND METHODS
Cell culture and xenografts
LNCaP, VCaP, 22Rv1 (ATCC, Manassas, VA) and 
LAPC4 cell line (obtained from Dr. Charles Sawyer), were 
maintained in phenol red-free ATCC-recommended media. 
Androgen-independent LNCaP cells (LNCaP-AI) [51], 
were maintained in phenol red-free RPMI1640 with 10% 
charcoal-stripped serum (CSS). Cell line identifies were 
established by short tandem repeat profiling (IDEXX). For 
reprogramming, cells were seeded on plates in standard 
parental media and, after overnight incubation, were 
switched to Stem-Transition Medium (STM). STM is 
formulated from phenol red-free KnockOut DMEM/F12 
(Gibco) supplemented with 2 mM GlutaMAX (Invitrogen), 
20 ng/mL rhbFGF (Gibco), 20 ng/mL rhEGF (Gibco) and 
2% StemPro Neural Supplement (Invitrogen). Medium was 
changed every 2–3 days. For re-differentiation paradigms, 
STM-reprogrammed cells were plated onto PEI-coated 
plates and allowed to attach overnight. Differentiation 
mediums were then added consisting of phenol red-free 
Neurobasal medium (Invitrogen) with B-27 Serum-Free 
Supplement (Invitrogen), 2% CSS, and 2 mM GlutaMAX 
(Invitrogen), for neuron re-differentation; the same plus 
30 ng/mL triiodothyronine (Sigma), for oligodendrocyte 
re-differentation; phenol-red free D-MEM with 1% N-2 
supplement (Invitrogen), 2% CSS, and GlutaMAX, for 
glia re-differentiation or; low-glucose phenol-red free 
DMEM, 10% CSS 10 mM B-glycerophosphate, 50 µg/ml 
ascorbate phosphate, 10 nM dexamethasone, and 
10 nM 25-dihydrovitamin D (Sigma), for osteoblast re-
differentiation. Re-differentiation to neuroendocrine-like cells 
employed phenol red-free RPMI-1640 with 10% CSS, and 
re-differentiation to prostate-like cells used RPMI-1640 with 
10% FBS, each for 14 days. For multiple reprogramming/
re-differentiation cycles, prostate re-differentiated cells 
were grown again in STM for 14 days then re-differentiated 
in FBS containing medium again for a total of 6 cycles to 
produce therapy resistant LNCaP-R6 cells.
Mouse xenografting
LNCaP xenografts were established and analysed as 
previously described [52]. After animals were euthanized, 
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tumors were removed, fixed in formalin and embedded 
in paraffin before sectioning and immunostaining. 
Xenografted mice were considered to be “positive” for 
tumors if the subcutaneous mass was equal to or greater 
than 150 mm3 within 6 weeks of xenografting and consisted 
of bulk tumor cells. All animal procedures were performed 
according to the guidelines of the Canadian Council on 
Animal Care and with appropriate institutional certification.
Microarray profiling
Gene expression profiling of cells were performed 
in biological triplicates with an Affymetrix (for LNCaP 
androgen deprivation) or Agilent (for STM-reprogrammed 
cells) human gene array platforms. Control parental 
LNCaP were grown in media supplemented with 10% 
charcoal-stripped serum (CSS) and 10 pM R1881, while 
androgen deprived LNCaP cells were cultured for 15 days 
in media supplemented with CSS alone before RNA 
extraction. RNAs were labeled using the WT labeling 
and control kit (Affymetrix) and were hybridized to 
GeneChip® Human Gene 1.0 ST Arrays. Arrays were 
scanned using Affymetrix Microarray Scanner System. 
To compare gene expression between parental PCa cells 
and STM-reprogrammed cells (LNCaP, VCaP, 22rv1 
and LAPC4), RNAs from biological triplicate samples 
of parental cells (cultured in phenol red-free media with 
FBS) and corresponding STM-reprogrammed cells (> 14 
days in STM) were extracted. Samples for gene expression 
analysis were prepared following Agilent’s One-Color 
Microarray-Based Gene Expression Analysis Low Input 
Quick Amp Labeling v6.0. An input of 100ng of total 
RNA was used to generate Cyanine-3 labeled cRNA. 
Samples were hybridized on Agilent SurePrint G3 Human 
GE 8x60K Microarray (AMDID 028004). Arrays were 
scanned with the Agilent DNA Microarray Scanner at a 3 
µm scan resolution and data was processed with Agilent 
Feature Extraction 11.0.1.1.
Database accession numbers 
Original gene expression microarray datasets 
have been uploaded to the GEO as public datasets under 
GSE66851 and. GSE66850. 
Clone formation assay
Approximately 300 LNCaP cells were plated on 
triplicate polyethylimine (PEI) coated 10cm plates. After 
24 hours cells were switched to STM or FBS. Medium 
was changed every 2–3 days for 14 days. Cells were fixed 
with 4% Paraformaldehyde (PFA) and stained with 0.05% 
Crystal Violet (Sigma-Aldrich) for 30 minutes before 
washing, and counting of colonies.
Spheroid assays
A single cell suspension of LNCaP was serially 
diluted to distribute roughly 5–10 cells per well into 
Ultra Low Adherence Round-Bottom 96-well plates 
(Corning) in 10% FBS, 10% CSS, or STM. Treatments 
were conducted 24 hours after plating, and medium/
treatments were topped up once every week. Spheroid 
formation was assessed by microscope imaging after 
two weeks, with a diameter threshold set at 100 µm to 
be considered a spheroid. Biological replicate data were 
analysed statistically by Two-Way ANOVA.
PSA quantification
PSA concentrations in 48 hour conditioned 
mediums were determined using the Cobas E411 
(Roche Diagnostics) immunoassay system following 
manufacturer’s instructions. PSA concentrations were 
normalised to the number of cells on the dish at the time 
of media harvest. Biological replicate data were analysed 
statistically by pair-wise Student’s T-test.
Western blotting
Cell lysates were prepared in RIPA buffer with 
protease and phosphatase inhibitors. Approximately 30µg 
to 50µg of protein were run on pre-cast 4–15% gradient 
gels (BioRad), and transferred to PVDF membranes. 
Detection was performed using peroxydase-conjugated 
and fluorescently-conjugated secondary antibodies. See 
Supplementary Materials and Methods for details of 
antibodies employed.
Quantitative real-time PCR
Total RNA was isolated using the RNeasy RNA 
Isolation Kit (Qiagen) before reverse transcription with 
Maxima kit (Thermo Scientific). Subsequent qPCR 
was performed using an ABI-ViiA7 with SYBR-Green 
detection (Applied Biosystems). Gene expression was 
normalized to the housekeeping gene RPL32. See 
Supplementary Table 5 for primer sequences employed 
for PCR amplification. Biological replicate data were 
analysed statistically by pair-wise Student’s T-test.
Proliferation assays
Cells were plated at 2000 cells/well in quadruplicate 
on a 96-Well Plate (Corning) on day -1. Experimental and 
control treatments were conducted and initial readings 
taken on day 0. CyQuant Direct Cell Proliferation Assay 
(Invitrogen) was employed for determination of live cell 
DNA content. Biological replicate data were analysed 
statistically by Two-Way ANOVA.
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Gene set enrichment analysis (GSEA) 
The GenePattern server (http://www.genepattern.
org/), and default parameters, were employed to identify 
significantly-enriched gene signatures in reprogrammed 
PCa cells (p < 0.05, fold change > 1.5). The gene sets 
used for enrichment were obtained from the “Curated” 
and “Hallmark” MSigDB collections. Custom gene sets, 
including the Kreitzer Neural Crest Stem Cell (GSE37859) 
and LNCaP xenograft progression series (GSE44319) 
were extracted from GEO and uploaded to GSEA as gene 
matrix files (.gmx).
Flow cytometry
Cells were detached by treatment with Accutase 
(Gibco), washed, incubated for 10 minutes with Human 
Fc-Blocker (eBioscience), then incubated with target 
antibodies for 30 minutes at 4°C. Cells were washed again 
and analysed on a FACSCanto™ II (BD Biosciences). 
See Supplementary Materials and Methods for details of 
antibodies employed. Data was analyzed using FlowJo 
software (TreeStar, USA). Biological replicates were 
analysed statistically by Two-Way ANOVA.
Immunofluorescence
For LNCaP and STM-reprogrammed LNCaP, 
cells were plated at 25,000 cells per well in 4 chamber 
slides coated with PEI. Cell were incubated for 48 hours 
before fixing in 1% PFA. Slides were washed once 
with PBS before permeabilization with 0.5% Triton (30 
minutes at room temperature). Cells were washed again 
before blocking in 3% milk for one hour, and overnight 
incubation with BRN3A and NESTIN antibodies. Cells 
were washed briefly before 1 hour incubation with 
secondary antibodies, and mounted in DAPI mounting 
media (Sigma). For differentiation to N/NC lineages, 
25,000 LNCaP-SL cells were plated in PEI coated 4 
chamber slides and allowed to attach for 24 hours before 
medium was replaced with osteoblast, neuron, glial, or 
oligodendrocyte re-differentiation medium. Media was 
refreshed every 3 days, and at day 8 cells were fixed and 
stained as described above. Immunofluorescence imaging 
was carried out on an Axio Observer Z1 Microscope (Carl 
Zeiss). See Supplementary Materials and Methods for 
details of antibodies employed.
Immunohistochemical staining
Immunohistochemical staining of tumor xenograft 
sections and spheroid sections was done on a Ventana 
autostainer model Discover XT (Ventana Medical 
System, Tuscan, Arizona) with an enzyme labeled biotin 
streptavidin system and solvent resistant DAB Map 
kit using corresponding primary antibody. For each 
biomarker, representative cores (clearly positive, clearly 
negative and mixed positive/negative) were manually 
identified by Dr. Ladan Fazli MD, Pathologist. 
Invasion assay
20,000 LNCaP and LNCaP-SL cells were seeded 
in the top chamber of a matrigel-coated 24-well plate 
inserts (Corning) in serum-free medium. 10% FBS was 
added to the lower chamber as a chemo-attractant. After 
20 hours, cells were fixed and stained with DAPI, the filter 
was fluorescently imaged and cells remaining on the filter 
counted.
Zebrafish metastasis assay
A wildtype zebrafish strain was maintained in 
aquaria according to standard protocols under approval 
of the Institutional Animal Care Committee. Embryos 
were dechorionated at 2 days post-fertilization. Parental 
and reprogrammed PCa cells were fluorescently labelled 
the day before microinjection with 1.5 μM of CellTracker 
CM-Dil dye (Life Technologies) per manufacturer’s 
instructions. Following anaesthetisation with Tricaine 
(Sigma-Aldrich), approximately 50–70 cancer cells were 
microinjected into the yolk sac of each fish. Embryos were 
then transferred to 100 mm2 plates that contained aquaria 
water with added phenylthiourea to prevent pigment 
formation. Approximately 50 fish were injected per cell 
line, and fluorescent cell dispersal throughout the fish was 
determined by observation using the Zeiss Axio Observer 
microscope at 5X objective. Images were then analyzed 
with Zen 2012 software. 
Correlation with cohorts of PCa patients
The 132-gene signature of reprogrammed PCa 
cells was correlated with clinically-annotated cohorts of 
PCa patients in the Mayo Clinic (MCI and MCII) [49, 
53], Cleveland Clinic Foundation (CCF) [54], and the 
Memorial Sloan Kettering (MSKCC) [55] patient cohorts. 
Statistical analyses were performed in R, version 3.2.2 and 
all statistical tests were two-sided using a 5% significance 
level. To test the significance of the association with 
outcome (biochemical recurrence, metastases, and prostate 
specific cancer mortality), Wilcoxon rank sum were used. 
The classifier was constructed using the glmnet package 
(glmnet 2.0–2). MCII Kaplan-Meier curve p-values were 
generated with a weighted Cox regression model (survival 
2.38–3). Detailed methodology for patient correlations are 
found in the Supplementary Materials and Methods.
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